Acknowledgement

The WHO Global Hepatitis Programme contracted EyeSeeTea Ltd to develop the DHIS2 module for global reporting for viral hepatitis, including the data entry forms and dashboards.
General information
The Global Reporting System for Hepatitis (GRSH) uses the District Health Information System Version 2 (DHIS2) tool. DHIS2 is a platform for reporting, analysing and disseminating data for health programmes. To use this platform, the person entering the data accesses a web browser and logs in.

1. Logging in
Users log in through the WHO DHIS2 website at https://extranet.who.int/dhis2/dhis-web-commons/security/login.action

Enter the user name and password to identify yourself within the system. This user name and password is unique to each user.

After login, the user is directed to the dashboard. The dashboard displays the data using various visuals. However, the information presented may vary for different users. Persons validating data from a country will see only the data for their country.

2. Validating aggregated numbers in the REPORTS application
Users validate aggregated numbers (cascade and sequelae) through the REPORTS application (app). From the dashboard, the user clicks on the upper-right field (a small box comprising several smaller boxes). This box provides access to the suite of apps available in this server. Select the REPORTS app.

Several sections are shown. To validate the aggregated data on cascade and sequelae, click on the last item, DATA APPROVAL.

2.1 Selecting the dataset

1. Within data approval, select the dataset for which to validate the data: HEPATITIS – CASCADE OF CURE AND CARE.

2. Select the year from the report period menu (for example, the reporting taking place in 2018 will correspond to the year 2017 as a reference period).

3. In the report organization unit should appear the country for which you are going to validate the data (within DHIS2, organization unit refers to the country).
4. Finally, click on the button **GET DATA** to access the data corresponding to the report you want to validate.

2.2 Data on testing and diagnosis (C6)

Validate the following data for both HBV and HCV:

- number of infected people already identified before the selected year (treated or not);
- number of people tested with serology (HBsAg/anti-HCV) in the selected year (including rapid tests*); and
- number of infected people newly diagnosed with infection in the selected year (HBsAg positive or HCV RNA or HCV core antigen positive, treated or not).

2.3 Data on treatment initiation and continuation (C7)

Validate the following data for HBV and/or HCV, as applicable:

* Needs to include testing activities conducted with rapid diagnostic tests.
● number of people continuing a treatment started before the year of reporting (only for HBV);
● total number of people newly starting treatment;*
● number of people newly starting treatment among people who injected drugs in the past 12 months (among the total above); and
● number of people completing treatment (only for HCV).

Note: In some cases, the question is only relevant to either HBV or HCV, and some fields are therefore disabled.

2.4 Data on treatment effectiveness (C8)

Validate the following data:

● number of people assessed for treatment effectiveness†; and
● number of people with effective treatment‡

2.5 Mortality from sequelae (C10)

Validate the following data:

● proportion of people dying from cirrhosis who were positive for viral hepatitis infection;
● proportion of people dying from hepatocellular carcinoma who were positive for viral hepatitis infection.

2.6 Approving data

Once all the data have been checked, press the APPROVE button at the top. A pop-up window will ask you for confirmation, and once you click OK, the data will be marked as approved.

This changes the status of the data and avoids any further modification. At this point, the data will be transmitted to WHO. If these data need to be corrected, this can be done later by clicking on the UNAPPROVE button that will appear in place of the APPROVE button.

---

* Regardless of eligibility (HBV infection).
† Tested for viral suppression with ALT or HBV DNA (HBV) or tested for sustained viral response using HCV RNA or HCV core antigen (HCV).
‡ Normal ALT or viral suppression (HBV) or sustained viral response (HCV).
Otherwise, this will mark the end of data validation.